Plasma Cystatin C and Acute Kidney Injury
This study is currently recruiting participants.
Verified August 2012 by Jinhua Central Hospital
Sponsor:
Jinhua Central Hospital
Information provided by (Responsible Party):
Hongying Ni, Jinhua Central Hospital
ClinicalTrials.gov Identifier:
NCT01652755
First received: July 26, 2012
Last updated: August 3, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the utility of plasma cystatin C(pCysC) as a predictive and diagnostic marker of acute kidney injury(AKI) in patients undergone cardiopulmonary bypass surgery.
| Condition |
|---|
|
Acute Kidney Injury |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery |
Further study details as provided by Jinhua Central Hospital:
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
AKI group
patients with AKI after cardiopulmonary bypass surgery
|
|
non-AKI group
patients without AKI during study period
|
Detailed Description:
This is a prospective AKI observational study in patients undergone cardiopulmonary bypass surgery. pCysC and plasma creatine will be measured at entry to ICU.AKI was defined as 50% increase in plasma creatine above baseline.The predictive and diagnostic performance of pCysC will be assessed from area under receiver operator characteristic curve(AUC) and odds ratio(OR).
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
patients undergone cardiopulmonary bypass surgery
Criteria
Inclusion Criteria:
- patients with CPB and admitted to ICU
Exclusion Criteria:
- patients with the age >80 or <18 years
- with preexisting renal dysfunction
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01652755
Contacts
| Contact: Hongying Ni, MM | 86 ext 57982552629 | nihongying2@163.com |
Locations
| China, Zhejiang | |
| Jinhua central hospital | Recruiting |
| Jinhua, Zhejiang, China, 321000 | |
| Contact: Hongying Ni, MM 86 ext 57982552629 nihongying2@163.com | |
| Principal Investigator: Hongying Ni, MM | |
Sponsors and Collaborators
Jinhua Central Hospital
Investigators
| Study Chair: | Hongying Ni, MM | Jinhua municipal central hospital |
More Information
No publications provided
| Responsible Party: | Hongying Ni, Department vice director, Jinhua Central Hospital |
| ClinicalTrials.gov Identifier: | NCT01652755 History of Changes |
| Other Study ID Numbers: | N-H-Y |
| Study First Received: | July 26, 2012 |
| Last Updated: | August 3, 2012 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Jinhua Central Hospital:
|
cystatin C,acute kidney injury, |
Additional relevant MeSH terms:
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases Cystatins |
Cysteine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013